Becton, Dickinson and Company (BDX)

Market Cap	67.92B
Revenue (ttm)	19.72B
Net Income (ttm)	1.32B
Shares Out	289.01M
EPS (ttm)	4.51
PE Ratio	52.11
Forward PE	16.79
Dividend	$3.80 (1.62%)
Ex-Dividend Date	Jun 10, 2024

Volume	1,025,023
Open	238.03
Previous Close	236.95
Day's Range	234.31 - 238.95
52-Week Range	229.40 - 287.32
Beta	0.47
Analysts	Buy
Price Target	288.83 (+22.91%)
Earnings Date	May 2, 2024

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascula...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 23, 1962
• Employees: 73,000
• Stock Exchange: NYSE
• Ticker Symbol: BDX

Financial Performance

In 2023, BDX's revenue was $19.37 billion, an increase of 2.66% compared to the previous year's $18.87 billion. Earnings were $1.42 billion, a decrease of -15.69%.

Analyst Forecast

According to 6 analysts, the average rating for BDX stock is "Buy." The 12-month stock price forecast is $288.83, which is an increase of 22.91% from the latest price.

Price Target

$288.83

(22.91% upside)

Analyst Consensus: Buy